tbuckley/cabot-search huggingface dataset:
228P Fulvestrant with additional palbociclib in advanced or metastatic hormone receptor-positive HER2-negative breast cancer after progression to fulvestrant monotherapy: JBCRG- M07 (FUTURE trial)
Authors: K. Watanabe, N. Niikura, Y. Kikawa, M. Oba, K. Kobayashi, H. Tada, S. Ozaki, U. Toh, Y. Yamamoto, M. Tsuneizumi, T. Okuno, N. Iwakuma, T. Takeshita, T. Iwamoto, H. Ishiguro, N. Masuda, S. Saji
Journal: Annals of Oncology (2022)
581P Homologous recombination deficiency (HRD) in 543 ovarian cancer samples: A single center hands-on experience
Authors: A. Kotsakis, P. Konstantoulakis, G. Christopoulou, S. Samara, A. Oikonomaki, K. Roumelioti, F. Pachitsa, F. Koinis, V. Georgoulias
Journal: Annals of Oncology (2022)
784O Adjuvant nivolumab (NIVO) alone or in combination with ipilimumab (IPI) versus placebo in stage IV melanoma with no evidence of disease (NED): Overall survival (OS) results of IMMUNED, a randomized, double-blind multi-center phase II DeCOG trial
Authors: D. Schadendorf, J.C. Hassel, M. Fluck, T. Eigentler, C. Loquai, S. Haferkamp, R. Gutzmer, F. Meier, P. Mohr, A. Hauschild, C. Menzer, F. Kiecker, E. Dippel, J-C. Simon, B. Conrad, C. Garbe, S. Körner, J.C. Becker, L. Zimmer, E. Livingstone
Journal: Annals of Oncology (2022)
702P Genomic alterations in epigenetic modifiers and response to epigenetic-targeted agents (ETAs) in patients (pts) with recurrent/metastatic (R/M) salivary gland tumours (SGTs)
Authors: M.A. Rezqallah Aron, A. Hernando-Calvo, V. Galvao de Aguiar, O. Saavedra Santa Gadea, J.D. Assaf Pastrana, M.J. Lostes Bardaji, K.I. Rojas Laimito, S. Aguilar Izquierdo, R. Berché, T. Tian, C. Bescós, J. Lorente, J. Giralt, J. Temprana-Salvador, M. Alberola, R. Dienstmann, E. Felip, E. Garralda, M. Vieito Villar, I. Brana
Journal: Annals of Oncology (2022)
846P Triple combination of ipilimumab + nivolumab + anti-TNF in treatment naive melanoma patients: Final analysis of TICIMEL, a phase Ib prospective clinical trial
Authors: N. Meyer, A. Lusque, M. Virazels, T. Filleron, C. Colacios, A. Montfort, B. Ségui
Journal: Annals of Oncology (2022)
436TiP COLSTAR: Randomized, open-label, multicentre, phase III study comparing futuximab/modotuximab plus trifluridine/tipiracil to trifluridine/tipiracil in KRAS/NRAS and BRAF wild type (wt) metastatic colorectal cancer (mCRC) previously treated with both standard and anti-EGFR treatment
Authors: F. Ciardiello, T. Yoshino, D.P. Modest, L. Martin Fernandez, L. Roby, R. Fougeray, B.P. Lockhart, J. Tabernero
Journal: Annals of Oncology (2022)
366P The PLK1 inhibitor onvansertib overcomes irinotecan resistance in RAS-mutated (mRAS) metastatic colorectal cancer (mCRC) in vivo and in patients (pts)
Authors: S. Kopetz, M. Ridinger, A. Sorokin, P. Kanikarla, F. Gao, Z. Liu, E. Samuelsz, T. Smeal, J.S. Starr, M.R. Sharma
Journal: Annals of Oncology (2022)
603P Multi-cancer early detection in gynaecological malignancies based on integrating multi-omics assays by liquid biopsy: A prospective study
Authors: H. Wen, Z. Feng, None H. Ge, C. Quan, X. Zhou, B. Yang, F. Liu, J. Wang, None Y. Wang, None J. Zhao, G. Zhou, X. Wen, Y. Liu, X. Zhu, G. Wang, Y. Zhang, B. Li, S. Cai, Z. Zhang, X. Wu
Journal: Annals of Oncology (2022)
925P Analytical performance of a next-generation sequencing (NGS) assay kit for assessing homologous recombination deficiency (HRD) from solid tumor samples
Authors: L. Liu, K. Roessler, S. Bilke, Y. Ding, D. Erlandson, Y. Fu, B. Hariharan, S. Katz, J. Lee, C. Schulman, F. Song, R. Vijayaraghavan, P. Wenz, E. Xia, H. Yan, Y. Zhu, C. Zhao, J. Dockter, T. Pawlowski, J. Day
Journal: Annals of Oncology (2022)
722P Modeling of tumor control probability (TCP) and normal tissue complications in individualized hypofractionated radiotherapy (IHRT) for large, advanced hepatocellular carcinoma (HCC)
Authors: S.M. Wong, C.L. Chiang, W.S. Wu, N.Y. Chan, W.Y. Lee, H.M.C. Ho, W.L.W. Yip, S.Y. Yeung, A.S. Lee, M.K.H. Chan, C.S.F. Wong
Journal: Annals of Oncology (2022)
723P Medical expenditures and treatment efficacy of patients who had initial hepatocellular carcinoma and underwent surgery or radiofrequency ablation: Accompanying research of the SURF trial
Authors: Y. Kawaguchi, R. Kita, T. Kimura, R. Goto, T. Takayama, N. Izumi, M. Kudo, S. Kaneko, N. Yamanaka, M. Inomata, M. Shimada, H. Baba, K. Koike, M. Omata, M. Makuuchi, Y. Matsuyama, Y. Yamada, N. Kokudo, K. Hasegawa
Journal: Annals of Oncology (2022)
889MO Comparative expression of driver transcription factors in extra-pulmonary small cell carcinoma
Authors: S. Puri, A. Elliott, H.P. Soares, E. Lou, B. Halmos, C.J. Langer, D. Uprety, S. Darabi, P. Walker, W. El-Deiry, A. VanderWalde, T.K. Owonikoko, S. Liu
Journal: Annals of Oncology (2022)
584P Mutation analysis of ovarian carcinoma patients presenting optimal response to neoadjuvant chemotherapy
Authors: E.S. Dos Santos, E. Yaniz Galende, S.M. Caputo, A.A.B.A. da Costa, M. Nashvi, F. Maella, L. Lacroix, A. Auguste, A. Le Formal, L. De Brot Andrade, V.C. Miranda, M.D. P.E. Diz, M. Vasconcelos, P. Pautier, P. Morice, C. Genestie, A. Leary, E. Rouleau
Journal: Annals of Oncology (2022)
528MO Is re-introduction or continuation of PARP inhibitors after local therapy for oligo-metastatic progression in patients with relapsed ovarian cancer relevant?
Authors: G. Thibault, M. Kfoury, D. Lorusso, A. Floquet, J. Ventriglia, H. Salaun, M. Moubarak, R. Rivoirard, L. Polastro, L. Favier, B. You, D. Berton-Rigaud, T. De La Motte Rouge, L. Mansi, C. Abdeddaim, K. Prulhiere, L. Lancry Lecomte, M. Provansal Gross, C. Dalban, I.L. Ray-Coquard
Journal: Annals of Oncology (2022)
804P Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: 5-year results of the EORTC 1325-MG/Keynote-054 double-blinded phase III trial
Authors: A.M.M. Eggermont, M. Kicinski, C.U. Blank, M. Mandala, G.V. Long, V.G. Atkinson, S. Dalle, A.M. Haydon, A. Meshcheryakov, A. Khattak, M.S. Carlino, S.K. Sandhu, S.S. Puig Sarda, P.A. Ascierto, P. Lorigan, D. Grebennik, N. Ibrahim, S.I. Marreaud, S. Suciu, C. Robert
Journal: Annals of Oncology (2022)
151P Tumor biology and immunology in patients (pts) with breast cancer occurring during pregnancy (BCP) compared to non-pregnant breast cancer pts
Authors: K. Galas, M. Gleitsmann, J. Rey, C. Solbach, I. Witzel, B. Seliger, T. Karn, S. Schmatloch, A. Schneeweiss, B.V. Sinn, T.N. Fehm, C. Denkert, A-S. Litmeyer, P. Jank, J. Furlanetto, O. Ortmann, M.T. Van Mackelenbergh, V. Nekljudova, S. Loibl
Journal: Annals of Oncology (2022)
103P Next generation sequencing (NGS) for the identification of PARP inhibitors’ predictive biomarkers
Authors: T. Floros, E. Papadopoulou, V. Metaxa-Mariatou, A. Tsantikidi, G. Kapetsis, C. Florou-Chatzigiannidou, A. Meintani, N. Touroutoglou, I. Boukovinas, F. Stavridi, C. Papadimitriou, D. Ziogas, M. Theochari, E. Timotheadou, A. Fassas, Z. Saridaki-Zoras, M. Ozdogan, U. Demirci, G. Nasioulas
Journal: Annals of Oncology (2022)
684P Liquid biopsy for detection of molecular residual disease and recurrence in head and neck squamous cell carcinoma
Authors: S. Flach, K. Howarth, S. Hackinger, C. Pipinikas, P. Ellis, K. McLay, G. Marsico, C. Walz, L. Käsmann, C.A. Reichel, O. Gires, M. Canis, P. Baumeister
Journal: Annals of Oncology (2022)
1048P Molecular predictors of immunotherapy efficacy in lung squamous-cell carcinoma (LSCC): Results from the randomized prospective SQUINT trial
Authors: F. Cappuzzo, A. Delmonte, L. Landi, K. Andrikou, A. Dal Maso, G. Minuti, C. Lee, X. Wang, M. Papi, G. Metro, I. Attili, F.V. Piantedosi, S. Pilotto, S. Gori, G. Rossi, S. Buglioni, D. Giannarelli, L. Bonanno
Journal: Annals of Oncology (2022)
996P Activity of OsimeRTInib in NSCLC with UNcommon EGFR Mutations: Retrospective observational multicenter study (ARTICUNO)
Authors: E.G. Pizzutilo, G. Cerea, S. Oresti, A.G. Agostara, D. Signorelli, S. Stabile, C. Lauricella, M. Brambilla, L. Mazzeo, R. Giusti, M. Montrone, M. Russano, C. Bennati, A. Russo, G. Viscardi, E. Roca, A.J. Gelibter, D.L. Cortinovis, A. Sartore Bianchi, S. Siena
Journal: Annals of Oncology (2022)
508P High prevalence of clonal hematopoiesis of indeterminate potential (CHIP) associated mutations in elderly patients with solid tumors
Authors: J.E. Rodriguez, A. Bayle, A. Pages, F-X. Danlos, D. Vasseur, E. Rouleau, L. Lacroix, V. Goldschmidt, L. Seknazi, A. Hollebecque, J-M. Michot, S. Champiat, A. Marabelle, S. Postel-Vinay, K. Ouali, C. Marzac, S. Ponce, A. Italiano, J. Baptiste Micol, C. Baldini
Journal: Annals of Oncology (2022)
169P Neoadjuvant pembrolizumab + chemotherapy followed by adjuvant pembrolizumab for treatment of high-risk, early-stage triple-negative breast cancer: A network meta-analysis
Authors: J. Cortés, A. Haiderali, M. Huang, W. Pan, G.E. Fox, J. Park, A.M. Frederickson, P.A. Fasching, J. O'Shaughnessy
Journal: Annals of Oncology (2022)
803P Patient-reported outcomes in patients with resected, stage III BRAF V600+ melanoma treated with adjuvant dabrafenib + trametinib: COMBI-APlus study
Authors: J.J. Grob, C. Dutriaux, M. Del Vecchio, B. Ryll, C. Robert, H.J. Gogas, A.M. Menzies, A. Gupta, H. Banerjee, M.R. Lau, V.G. Atkinson
Journal: Annals of Oncology (2022)
646TiP VITALIZE: A phase IIb, open-label, multicenter, randomized parallel-group, two-stage, study of maveropepimut-S, pembrolizumab, with or without intermittent low-dose cyclophosphamide, in r/r DLBCL
Authors: M. Matasar, J. Teti, K. Mody, S. Fiset, J. Graff
Journal: Annals of Oncology (2022)
268P Results from a real-world study of patients (pts) with hormone-receptor (HR)-positive HER2-negative metastatic breast cancer (MBC) treated with CDK4/6 inhibitors (CDK 4/6i) in three institutions
Authors: H. Pla, S. Recalde Penabad, G. Vinas Villaro, M. Margeli Vila, V.L. Obadia Gil, B. Cirauqui Cirauqui, S. Del Barco Berron, M.J. Gil, V. Quiroga Garcia, I. Teruel-Garcia, S. Pernas Simon, A. Stradella, A.M. Esteve Gomez, E. Felip
Journal: Annals of Oncology (2022)
965P Real-world toxicity of consolidation durvalumab following chemoradiotherapy (CRT) in elderly and comorbid patients (pts) with unresectable stage III NSCLC: A multi-centre, Australian experience
Authors: S. Stevens, U. Nindra, A. Shahnam, V. Bray, A. Pal, P.Y. Yip, T. Adam, A. Nagrial, J.H. Lee, M. Boyer, S.C-H. Kao
Journal: Annals of Oncology (2022)
1040P Nivolumab or atezolizumab in the second-line treatment of advanced non-small-cell lung cancer? Prognostic index based on real-world data
Authors: M. Knetki-Wroblewska, A. Płużański, S. Tabor, K. Winiarczyk, M. Zaborowska-Szmit, K. Zajda, A. Janowicz Zebrowska, A. Piórek, P. Badurak, P. Jaśkiewicz, D.M. Kowalski, M.J. Krzakowski
Journal: Annals of Oncology (2022)
665P Retinal vessels characteristics analysis as a predictive tool for post-radiation neurocognitive impairment in patients with nasopharyngeal cancer
Authors: J.C-H. Chow, J. Lee, M.M.P. Lai, S.X.X. Li, A.Y.L. Lau, B.S.Y. Ng, G.G. Leung, S.T.Y. Li, K.M. Cheung, A.M.C. Lau, K.H. Au, B.C.Y. Zee
Journal: Annals of Oncology (2022)
1016P GFPC 06-2018: A multicentre phase II, open-label, non-randomized study evaluating platinum-pemetrexed-atezolizumab (+/- bevacizumab) for patients with stage IIIB/IV non-squamous NSCLC with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies
Authors: O. Bylicki, R. Gervais, I. Monnet, C. Ricordel, L. Bigay-Game, M. Geier, C. Decroisette, C. Daniel, F. Guisier, A. Swalduz, A.C. Toffart, H. Doubre, J.M. Peloni, D. Arpin, H. Morel, R. Veillon, B. Clarisse, P-H. Martins-Lavinas, L. Greillier, C. Chouaid
Journal: Annals of Oncology (2022)
989P Sotorasib in advanced KRAS p.G12C-mutated non-small cell lung cancer (NSCLC): Safety and efficacy data from the global expanded access program (EAP)
Authors: M. Awad, G. Pelizzari, J.P. Stevenson, M. Majem Tarruella, C.G.M. Ferreira, W.J. Petty, E. Arriola, J. de Castro, I. Morbeck, J.R. Bauman, L. Toschi, A. Zer, G. Metro, S. Kalmadi, A. Azkárate Martínez, C. Xia, A. Meloni, C. Obiozor, N. Maimon, S. Novello
Journal: Annals of Oncology (2022)
1018P Phase I/II trial of rigosertib and nivolumab for KRAS mutated non-small cell lung cancer (NSCLC) patients
Authors: R. Veluswamy, S. Bhalla, R. Samstein, T. Marron, J.E. Gomez, D.B. Doroshow, J. Sabari, E. Shum, A. Saxena, A. Namakydoust, A. Chachoua, J. Wisnivesky, J. Mandeli, N. Bhardwaj, F.R. Hirsch, M. Merad, E. Reddy
Journal: Annals of Oncology (2022)
158P The impact of tumor microenviroment on pathologic complete response after neoadjuvant chemotherapy of early breast cancer
Authors: C. Grasic Kuhar, B. Gazić, A. Klevišar Ivančič, P. Drev, M.H.F. Vetter, C. Kurzeder, K. Geršak
Journal: Annals of Oncology (2022)
680P HANNA: Real-world data of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN), including first-line population, treated with nivolumab in Germany
Authors: C. Langer, E. von der Heyde, D.A. Hahn, B. Kubuschok, U. Bockmühl, H. Mueller-Huesmann, G. Klautke, J. von der Grün, D. Beutner, J. Büntzel, C-J. Busch, B.F. Tamaskovics, J. Riera Knorrenschild, K. Gutsche, M.K. Welslau, T.C. Gauler, D. Waldenberger, A. Dietz
Journal: Annals of Oncology (2022)
661MO Evaluation of the DNA damage response (DDR) network as predictor of nivolumab efficacy in head and neck squamous cell carcinoma (HNSCC)
Authors: P. Economopoulou, C. Papanikolaou, A. Spathis, I. Kotsantis, N. Gavrielatou, M. Anastasiou, D. Stellas, I. Panayiotides, P. Foukas, V.L. Souliotis, A. Psyrri
Journal: Annals of Oncology (2022)
988P Phase I/II study of mobocertinib in EGFR exon 20 insertion (ex20ins) + metastatic NSCLC (mNSCLC): Updated results from platinum-pretreated patients (PPP)
Authors: S.S. Ramalingam, C. Zhou, T.M. Kim, J.C-H. Yang, G.J. Riely, T. Mekhail, D. Nguyen, M.R. Garcia Campelo, E. Felip, D. Misch, M. Kaur, V. Bunn, M. Lin, P. Zhang, P.A. Jänne
Journal: Annals of Oncology (2022)
523MO Ubamatamab (REGN4018, MUC16xCD3 bispecific antibody) monotherapy in patients with recurrent ovarian cancer (OC): Phase I dose-escalation analysis
Authors: E. Van Nieuwenhuysen, D. O'Malley, R.E. O'Cearbhaill, K.N. Moore, E.P. Hamilton, O. Yeku, S. Bouberhan, J.Y. Hou, S-Y. Yoo, J. Brouwer-Visser, H.K. Cheung, M. Peterman, P. Goncalves, T. Schmidt, M. Zhu, I. Lowy, T. Rowlands, T.S. Uldrick, E.A. Miller, J.F. Liu
Journal: Annals of Oncology (2022)
321P A comprehensive predicting model of recurrence in stage III colon cancer from PETACC-8 trial
Authors: C. Gallois, M. Sroussi, S. Mouillet-Richard, C. Mulot, L.M. Dourthe, T. Mazard, M. Jary, C. de la Fouchardiere, C. Lecaille, W. Lahlou, J. Tabernero, J-L. van Laethem, C. Lepage, J.F. Emile, J. Taieb, A. de Reynies, P. Laurent-Puig
Journal: Annals of Oncology (2022)
935P Demographics, clinical characteristics, treatment patterns and clinical outcomes of patients with stages I-III resected NSCLC without known EGFR mutations
Authors: N.K. Altorki, R. Salomonsen, N.E. Georgoulia, I. Diaz Perez, A. Wang, L. Cai, G. Wetherill, Y. Xiao, C. Fielden, J.E. Gray
Journal: Annals of Oncology (2022)
379P Whole exome sequencing of plasma circulating tumor DNA identifies dynamic mutational changes to guide targeted therapies in colon cancer patients
Authors: J. Martín-Arana, F. Gimeno-Valiente, R. Tébar-Martínez, B. García-Mico, V. Gambardella, M. Huerta, C. Martínez-Ciarpaglini, J.A. Carbonell-Asins, M. Cabeza Segura, J. Martín-Arévalo, D. Casado, V. Pla, L. Pérez, P. Rentero-Garrido, S. Rosello Keranen, T.C. Fleitas, J. Castillo, D. Roda Perez, A. Cervantes, N. Tarazona Llavero
Journal: Annals of Oncology (2022)
716P Impact of COVID-19 pandemic on clinical outcomes in hepatocellular carcinoma: A multicentre cohort study
Authors: S. De Souza, J. Kahol de Jong, R. Jones, H. Reeves, S. Shetty, J. Orr, D. Bettinger, V. Yip, L. Temperley, D. Geh, M. Qurashi, B. Allen, L. Sturm, A. Banerjee, P. Ross, R. Sharma
Journal: Annals of Oncology (2022)
147P Blind validation of an AI-based tool for predicting distant relapse from breast cancer HES stained slides
Authors: I.J. Garberis, V. Gaury, V. Aubert, D. Drubay, C. Saillard, K. Elgui, None F. Bernigole, A. Jacquet, F. André, M. Lacroix-Triki
Journal: Annals of Oncology (2022)
208P Automated prognosis marker assessment in 2’004 breast cancers using an artificial intelligence-based framework for BLEACH&amp;STAIN mfIHC
Authors: T. Mandelkow, E. Bady, J.H. Müller, N.F. Debatin, M.C.J. Lurati, C. Hube-Magg, G. Sauter, N.C. Blessin
Journal: Annals of Oncology (2022)
587P Sequential approach to determine the HRD status with BRCA1 promotor methylation status and shallow whole genome sequencing (sWGS)
Authors: E. Rouleau, F. Blanc-Durand, M. Nashvi, S. Cotteret, C. Genestie, A. Le Formal, M. Pommier, D. Vasseur, Y. Adnani, L. Lacroix, A. Leary, R. Tang
Journal: Annals of Oncology (2022)
425P Novel CoupledCAR technology for treating colorectal cancer
Authors: J. Cui, N. Chen, C. Pu, L. Zhao, C. Wang, R. Zhu, T. Liang, X. Huang, H. Tang, Y. Wang, H. Yang, B. Jia, W. Wang, D. Chen, E. Kennedy, G. Cui, Z. Wu, L. Xiao
Journal: Annals of Oncology (2022)
351P Prevalence of ERBB alterations in colorectal cancer patients using genomic profiling
Authors: M.N. Kundranda, M. Wang, D.W. Hall, J. Hoag, F. Alyaqoub, P. Noel, S. Szelinger, S.S. Udhane, A.A. Ozols, J.R. Lobello, F.L. Baehner, S.G. Thakkar
Journal: Annals of Oncology (2022)
890MO Mutation spectrum in liquid versus solid biopsies from advanced digestive neuroendocrine carcinoma patients
Authors: H. Sorbye, S. Knappskog, T. Grob, A. Venizelos, U. Amstutz, G.O. Hjortland, I.M. Lothe, C. Kersten, E. Hofsli, A. Sundlov, H. Elvebakken, H. Garresori, A. Couvelard, J. Svensson, A. Perren
Journal: Annals of Oncology (2022)
985P Tepotinib outcomes according to prior therapies in patients with MET exon 14 (METex14) skipping NSCLC
Authors: E.F. Smit, M.C. Garassino, E. Felip, H. Sakai, X. Le, R. Veillon, J. Mazieres, A. Cortot, J. Raskin, M. Thomas, S. Viteri Ramirez, K. Berghoff, R. Bruns, G.P. Otto, P.K. Paik
Journal: Annals of Oncology (2022)
232P Second-line therapies of patients with early progression under CDK4/6-inhibitor in first-line – data from the registry platform OPAL
Authors: N.W. Marschner, N. Harbeck, M. Thill, E. Stickeler, M. Zaiss, A. Nusch, J. Rauh, H. Schulz, K. Engelken, L. Kruggel, M. Jänicke, M-O. Zahn, A. Wöckel, A. Welt, T. Decker
Journal: Annals of Oncology (2022)
117P BiomeOne: Multi-centric validation of a novel microbiome-based biomarker to predict response to cancer immunotherapy
Authors: I. Robinson, M. Schmidinger, M.J. Hochmair, L. Ay, G. Absenger, M. Pichler, V.A.F. Nguyen, E. Richtig, B. Rainer, C. Jansen, B. Sladek, A. Knabl, N. Gasche, A. Valipour
Journal: Annals of Oncology (2022)
596P CA125 longitudinal decline kinetic is complementary to BRCA testing in first-line high grade serous ovarian carcinoma (HGSOC) patients (pts)
Authors: O. Becker, M. Chevrier, L. Gladieff, F. Joly Lobbedez, I.L. Ray-Coquard, A. Floquet, C. Pomel, H. Costaz, P. Pautier, T. De La Motte Rouge, R. Sabatier, J-M. Classe, E. Leblanc, F. Marchal, P-E. Colombo, E. Barranger, O. Colomban, L. Bosquet, B. You, M.J. Rodrigues
Journal: Annals of Oncology (2022)
1060P Impact of baseline clinicopathologic and genomic features on outcomes to KRAS G12C inhibitors in patients with NSCLC
Authors: G. Lamberti, A.J. Cooper, B. Ricciuti, J.V. Alessi, A.P. de Castro Barrichello, F. Pecci, V.R. Vaz, M. Nishino, L.M. Sholl, R. Heist, M. Awad
Journal: Annals of Oncology (2022)
973MO KEYNOTE-189 5-year update: First-line pembrolizumab (pembro) + pemetrexed (pem) and platinum vs placebo (pbo) + pem and platinum for metastatic nonsquamous NSCLC
Authors: M.C. Garassino, S.M. Gadgeel, G. Speranza, E. Felip, E. Esteban Gonzalez, M. Domine Gomez, M.J. Hochmair, S.F. Powell, H. Bischoff, N. Peled, F. Grossi, R. Jennens, M. Reck, R. Hui, E.B. Garon, T. Kurata, J.E. Gray, P.O. Schwarzenberger, E. Jensen, D. Rodriguez Abreu
Journal: Annals of Oncology (2022)
459MO Phase Ia study to evaluate GDC-6036 monotherapy in patients with solid tumors with a KRAS G12C mutation
Authors: M. Patel, J-S. Lee, M.J. De Miguel, T. Burns, A. Falcon Gonzalez, T.W. Kim, M.G. Krebs, H. Prenen, E. Shacham Shmueli, J. Desai, P. Lorusso, A. Sacher, Y. Choi, N. Dharia, M.T. Lin, S. Mandlekar, S. Royer-Joo, J.L. Schutzman, E. Garralda
Journal: Annals of Oncology (2022)
388P Early tumor shrinkage (ETS) and depth of response (DpR) analyses in metastatic colorectal cancer (mCRC) treated with first-line mFOLFOX6 plus panitumumab (PAN) or bevacizumab (BEV): Results from the phase III PARADIGM trial
Authors: K. Muro, J. Watanabe, K. Shitara, K. Yamazaki, H. Ohori, M. Shiozawa, H. Yasui, E. Oki, T. Sato, T. Naitoh, Y. Komatsu, T. Kato, M. Hihara, J. Soeda, K. Yamamoto, K. Akagi, A. Ochiai, H. Uetake, K. Tsuchihara, T. Yoshino
Journal: Annals of Oncology (2022)
134O Dose-dense adjuvant chemotherapy in early-stage breast cancer patients: End-of-study results from a randomised, phase III trial of the Gruppo Italiano Mammella (GIM)
Authors: L. Del Mastro, F. Poggio, E. Blondeaux, S. de Placido, M. Giuliano, M. De Laurentiis, G. Bisagni, M. Cantore, A. Turletti, C. Nisticò, Y. Urracci, O. Garrone, C. Bighin, M. Mansutti, F. Montemurro, G. Colantuoni, M. Lambertini, L. Boni
Journal: Annals of Oncology (2022)
805P Predicting recurrence-free survival for patients with stage II melanoma: A validated tool to guide selection for adjuvant systemic therapy
Authors: A.H.R. Varey, M-A. El Sharouni, J. Simon, J.E. Gershenwald, G.V. Long, R.A. Scolyer, J.F. Thompson, S.N. Lo
Journal: Annals of Oncology (2022)
73P Multi-cancer early detection through evaluation of aneuploidy, methylation, and protein biomarkers in plasma
Authors: C. Douville, C. Nobles, H.J. Hwang, V.E. Katerov, V. Gainullin, J. Tong, K. Ushakov, A. Koenig, H. Guttman, M. Jaime, J. Wang, W. Ault, M.M. Gray, G.C. Cerqueira, C. Lengauer, J. Garces, A. McElhinny, H.T. Allawi, F. Diehl
Journal: Annals of Oncology (2022)
348P Prediction of sensitivity to anti-EGFR inhibitors in salvage-line treatment for metastatic colorectal cancer using a modified MethyLight assay
Authors: K. Ouchi, S. Takahashi, H. Osumi, Y. Otsuki, None K. Sasaki, E. Shinozaki, C. Ishioka
Journal: Annals of Oncology (2022)
210O Mutational signature analysis reveals patterns of genomic instability linked to resistance to endocrine therapy (ET) +/- CDK 4/6 inhibition (CDK4/6i) in estrogen receptor-positive/HER2-negative (ER+/HER2-) metastatic breast cancer (MBC)
Authors: A. Marra, A. Gazzo, A. Gupta, P. Selenica, E.M. Da Silva, F. Pareja, X. Pei, Y. Zhu, P. Razavi, A. Safonov, E. Ferraro, R. Harris, N. Riaz, J.S. Reis-Filho, S. Chandarlapaty
Journal: Annals of Oncology (2022)
1054P Impact of intratumoral microbiome on immunotherapy treatment outcomes in patients with advanced non-small cell lung cancer
Authors: A. Elkrief, A. Bowman, H. Rizvi, M. Hellmann, G.J. Riely, A.J. Schoenfeld, M. Ladanyi, C.M. Vanderbilt
Journal: Annals of Oncology (2022)
263P Clinical outcomes in patients with germline pathogenic variants in homologous recombination repair (HRR) genes treated with CDK4/6 inhibitors (CDK4/6i) and endocrine therapy (ET)
Authors: A. Rodriguez Hernandez, O. Martinez Saez, F. Brasó-Maristany, B. Pastor, M. Potrony, L. Moreno, E. Grau, J.A. Puig-Butille, A. Sánchez, F. Schettini, B. Conte, N. Chic, M.J. Vidal Losada, M. Munoz, F. Balaguer, A. Prat, B. Adamo
Journal: Annals of Oncology (2022)
513MO Risk and mortality of testicular cancer in patients with psychiatric or neurodevelopmental disorders
Authors: A.K. Jansson, J. Söderling, J. Reutfors, A. Thor, C. Sköld, G. Cohn-Cedermark, O. Ståhl, K. Ekström Smedby, A. Pettersson, I. Glimelius
Journal: Annals of Oncology (2022)
875P Trends in melanoma incidence among women living in North-East Italy 2000-2020: Population-based study
Authors: D. Serraino, F. Toffolutti, L. Dal Maso, T. Angelin, L. Fratino, M.A. Pizzichetta, A. Palumbo, O. Forgiarini, E. De Santis, E. Bidoli
Journal: Annals of Oncology (2022)